Cofetuzumab pelidotin

Drug Profile

Cofetuzumab pelidotin

Alternative Names: PF-06647020; PF-6647020; PTK7-ADC

Latest Information Update: 12 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Stemcentrx
  • Developer Pfizer; Stemcentrx
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action PTK7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 14 Aug 2017 Indiana University plans a phase I trial for Breast cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (NCT03243331)
  • 10 Apr 2017 Pfizer re-initiates enrolment in a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in Spain and USA (IV) (NCT02222922)
  • 07 Oct 2016 Interim efficacy and safety from a phase I trial in Solid tumours were presented at 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top